

Assays for Safety Pharmacology

Safety pharmacology helps identify and prevent off-target effects caused by drugs interacting with unintended biological targets. Issues, such as drug-drug interactions or toxicity, can derail the development process, potentially leading to failed clinical trials or even post-market withdrawals. Early identification of off-target effects enables design modifications, ultimately contributing to a safer drug profile. INDIGO's comprehensive assay portfolio equips you with the tools needed to identify such issues before they become problematic.

Safety Pharmacology Screening Solutions

INDIGO Biosciences offers a variety of high-throughput assays designed for safety pharmacology screening of off-target effects across multiple pathways:

Nuclear Receptor Assays: With assays for more than 30 nuclear receptors, INDIGO enables you to identify off-target interactions with key receptors that play a critical role in drug metabolism, endocrine disruption, steatosis, and toxicity.

Hepatotoxicity Assay: Use this assay for *in vitro* screening of drug-induced hepatotoxicity.

CYP450 Screening Assay: INDIGO's CYP450 Screening Assay identifies drugs that may cause enzyme induction or inhibition, leading to toxicity or altered drug clearance.

P-glycoprotein (Pgp) Assay: This assay predicts whether your drug will interfere with Pgp transporters, potentially leading to toxic accumulation in tissues or poor absorption.

Benefits of INDIGO's Safety Pharmacology Screening Portfolio

Early Risk Detection

Identify off-target interactions early in discovery, reducing the risk of adverse events, failed trials, and increasing your drug's chances of success.

Comprehensive Coverage

With assays targeting nuclear receptors, GPCRs, cytokine receptors, and more, INDIGO's portfolio covers the critical pathways for off-target effects.

Fast Results, Reliable Data

INDIGO assays deliver results in as little as 24 hours, providing you with the data you need to make informed decisions quickly.

